A validation study of auditory function in an aminoglycoside-furosemide ototoxicity mouse model: Auditory brainstem response and distortion product otoacoustic emissions

Sensorineural hearing loss due to ototoxic drugs remains as a conflict as the treatment option with aminoglycosides. Ototoxic mouse model was produced with the administration of ototoxic drugs aminoglycoside kanamycin and loop-diuretic furosemide, thus validation of auditory function of the mouse model is needed to determine the efficacy of the drugs. Kanamycin sulfate 550 mg/kg (VWR life sciences, PA, USA) and furosemide 130 mg/kg (Lasix, Handok, Korea) were administered through subcutaneous and intraperitoneal injection respectively. Auditory brainstem response and distortion otoacoustic emission tests were performed on days 3,5,7,10,14 post administration of the ototoxic drug. Thresholds in response to the stimulus given in the auditory brainstem recordings and distortion otoacoustic emission tests were obtained. The hearing threshold shift to high stimulus intensity was observed post administration of the ototoxic drug. Latency of the ABR peak waves were recorded and analyzed, latency delay was observed as hearing threshold increases. These findings will further support in the application of this animal model in various studies regarding ototoxic hearing loss.